Loading...

PE anti-mouse CD152 Antibody

Pricing & Availability
Clone
UC10-4B9 (See other available formats)
Regulatory Status
RUO
Other Names
Cytotoxic T Lymphocyte-Associated Antigen-4 (CTLA-4), Ly-56
Isotype
Armenian Hamster IgG
Ave. Rating
Submit a Review
Product Citations
publications
UC10-4B9_PE_090507
Con A+IL-2-stimulated BALB/c splenocytes (day-2) were stained with CD3 APC and UC10-4B9 PE
  • UC10-4B9_PE_090507
    Con A+IL-2-stimulated BALB/c splenocytes (day-2) were stained with CD3 APC and UC10-4B9 PE
Compare all formats See PE spectral data
Cat # Size Price Quantity Check Availability Save
106305 50 µg 88€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
106306 200 µg 264€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD152, also known as CTLA-4 or Ly-56, is a 33 kD member of the immunoglobulin superfamily. It is expressed on activated T and B lymphocytes. CD152 is similar to CD28 in amino acid sequence, structure, and genomic organization and these two receptors share common B7 family counter-receptors (B7-1, B7-2). Whereas CD28 delivers a costimulatory signal in T cell activation, CTLA-4 negatively regulates cell-mediated immune responses. CD152 is thought to play a role in the induction and maintenance of immunological tolerance as well as the development of protective immunity and thymocyte regulation.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Armenian Hamster
Immunogen
Mouse CTLA-4-mouse IgG2a fusion protein
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

The UC10-4B9 antibody can enhance T cell co-stimulation by blocking CTLA-4 interactions with the B7 co-receptors, favoring CD28 interactions. Additional reported applications (for the relevant formats) include: immunoprecipitation1, in vitro stimulation, in vitro and in vivo blocking1-4 of ligand binding, and as ELISA capture antibody5. To reduce non-specific binding to cells bearing Fc-receptors, pre-incubation of cells with anti-mouse CD16/CD32, clone 93 (Cat. No. 101301/101302), is recommended prior to immunofluorescent staining. For most successful immunofluorescent staining results, it may be important to maximize signal over background by using a relatively bright fluorochrome-antibody conjugate (Cat. No. 106306) or by using a high sensitivity, three-layer staining technique (e.g., including a biotinylated anti-Armenian hamster IgG (Cat. No. 405501) second step, followed by SAv-PE (Cat. No. 405204)). The Ultra LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 106327).

Application References

(PubMed link indicates BioLegend citation)
  1. Walunas TL, et al. 1994. Immunity 1:405. (Block, IP)
  2. Cilio CM, et al. 1998. J. Exp. Med. 188:1239. (Block)
  3. Issazadeh S, et al. 1999. J. Immunol. 162:761. (Block)
  4. McCoy K, et al. 1997. J. Exp. Med. 186:183. (Block)
  5. Hsu HC, et al. 2007. J. Immunol. 178:5357. (ELISA Capture)
  6. Sugita S, et al. 2010. Invest. Ophthalmol. Vis. Sci. 51:5783. PubMed
Product Citations
  1. Logan K Smith et al. 2018. Immunity. 48(2):299-312 . PubMed
  2. Schwarz A, et al. 2023. Front Immunol. 14:1038689. PubMed
  3. Xiao X, et al. 2023. Nat Commun. 14:2859. PubMed
  4. Saxena V, et al. 2022. Cell Rep. 39:110727. PubMed
  5. Broadfield LA, et al. 2022. Mol Metab. 61:101498. PubMed
  6. Que W, et al. 2022. Sci Adv. 8:eabo4413. PubMed
  7. Ivasko SM, et al. 2023. Front Immunol. 13:1023206. PubMed
  8. Zenke S, et al. 2022. Nat Commun. 13:6459. PubMed
  9. Wang L, et al. 2019. Cell Rep. 29:1848. PubMed
  10. Denk D, et al. 2022. Immunity. 55:2059. PubMed
  11. Qi Z, et al. 2022. Nat Commun. 13:182. PubMed
  12. Shi B, et al. 2018. J Immunol. 200:586. PubMed
  13. Turner JA, et al. 2020. Immunity. 53:1202. PubMed
  14. Sugita S, et al. 2010. Invest Ophthalmol Vis Sci. 51:5783. PubMed
  15. Wu M, et al. 2021. Nat Commun. 12:3500. PubMed
  16. DeLong JH, et al. 2019. Immunohorizons. 3:13. PubMed
  17. Alikhan M, et al. 2016. J Am Soc Nephrol. 27: 706 - 714. PubMed
  18. An J, et al. 2022. iScience. 25:103570. PubMed
  19. Thauland T, et al. 2014. J Immunol. 193:5894. PubMed
  20. Singh K, et al. 2015. Sci Rep. 14:7767. PubMed
  21. Wei SC, et al. 2020. Cancer Discov. . PubMed
  22. Xu L et al. 2017. Immunity. 47(3):538-551 . PubMed
  23. Miska J et al. 2019. Cell reports. 27(1):226-237 . PubMed
  24. Espinosa JR, et al. 2018. Front Immunol. 9:1371. PubMed
  25. Ren J, et al. 2019. PLoS Biol. 17:e3000270. PubMed
  26. Jing Y, et al. 2020. Sci Adv. 6:eaax9455. PubMed
  27. Harb H, et al. 2021. Immunity. 54(6):1186-1199.e7. PubMed
  28. Andersen L, et al. 2020. Cell Reports. 29(13):4447-4459.e6.. PubMed
  29. De Ponte Conti B, et al. 2021. Elife. 10:. PubMed
  30. Benci JL et al. 2019. Cell. 178(4):933-948 . PubMed
  31. Wedekind MF, et al. 2021. iScience. 24(7):102759. PubMed
  32. Elliot TAE, et al. 2021. Immunity. 54:2481. PubMed
  33. Zhang GL, et al. 2020. Matrix Biol. 93:25. PubMed
  34. Hu J, et al. 2022. J Immunother Cancer. 10:. PubMed
  35. Montalban-Arques A, et al. 2021. Cell Host Microbe. :. PubMed
  36. Halim TYF et al. 2018. Immunity. 48(6):1195-1207 . PubMed
  37. Li J, et al. 2021. Cell Rep. 37:110124. PubMed
  38. Rinaldi S, et al. 2021. PLoS Pathog. 17:e1009533. PubMed
  39. Xu C, et al. 2021. Cell Reports. 35(11):109235. PubMed
  40. Timilshina M, et al. 2020. Cell Reports. 27(10):2948-2961.e7.. PubMed
  41. Yang FM, et al. 2022. Front Immunol. 13:918241. PubMed
  42. Katsuyama T, et al. 2021. Cell Reports. 36(1):109339. PubMed
RRID
AB_313254 (BioLegend Cat. No. 106305)
AB_313254 (BioLegend Cat. No. 106306)

Antigen Details

Structure
Ig superfamily, 33 kD
Distribution

Activated T cells and B cells

Function
Negative regulator of T cell activation
Ligand/Receptor
CD80 (B7-1), CD86 (B7-2)
Cell Type
B cells, T cells, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules, Immune Checkpoint Receptors
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Allison JP, et al. 1995. Science 270:932.
3. Waterhouse P, et al. 1995. Science 270:985.
4. Linsley PS, et al. 1991. J. Exp. Med. 174:561.

Gene ID
12477 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
CD152
Specificity Alt (DOES NOT SHOW ON TDS):
CD152
App Abbreviation (DOES NOT SHOW ON TDS):
FC
UniProt
View information about CD152 on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.
Go To Top Version: 2    Revision Date: 04/18/2014

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account